CADL•benzinga•
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?
Summary
Candel Therapeutics stock rose after its prostate cancer therapy, CAN-2409, received FDA RMAT designation. This expedites development and review, following positive Phase 3 trial results.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 28, 2025 by benzinga